Skip to content

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)

A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Subjects With Knee Osteoarthritis

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00704847
Enrollment
1030
Registered
2008-06-25
Start date
2008-06-30
Completion date
2011-06-30
Last updated
2019-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Keywords

Osteoarthritis, oral salmon calcitonin, treatment, efficacy,, tolerability

Brief summary

The purpose of this phase III study is to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Patients with Osteoarthritis of the Knee

Interventions

0.8mg SMC021, twice daily

DRUGOral Salmon Calcitonin (Placebo)

0.8mg Placebo, twice daily

Sponsors

Novartis
CollaboratorINDUSTRY
Nordic Bioscience A/S
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
51 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Medical history and symptoms of knee osteoarthritis

Exclusion criteria

* Any other disease or medication affecting the bone or cartilage. * Any clinical signs or laboratory evidence diseases, which in the Investigator's opinion would preclude the participant from adhering to the Protocol or completing the trial. Other protocol defined inclusion/

Design outcomes

Primary

MeasureTime frameDescription
Joint Space Width (JSW) in the Medial Tibia-femoral Knee Joint in the Signal Knee Measured by X-ray Change From Baseline Over 24 MonthsChange from baseline to 24 monthsThe signal knee was chosen prior to randomization based on which knee met the inclusion and exclusion criteria. The JSW is the space measured in mm between the 2 bones in the knee joint and this is assessed by x-ray. The JSW decreases with disease progression. The lower limit for participation in the trial were 2 mm JSW. There were no upper limit as long as inclusion and exclusion criteria were met. The outcome was measured as a change in JSW from baseline to month 24.
Pain Subscore Change From Baseline Over 24 Months as Assessed by Western Ontario and McMaster Universities Arthritis (WOMAC) IndexChange from baseline to 24 monthsWOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the pain associated with performing each daily activity listed in the questionnaire. 0 is no pain (best), 100 is extreme pain (Worst). The total pain sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 500. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less pain).

Secondary

MeasureTime frameDescription
Questionnaire to Assess Function and Physical ActivityFrom baseline to months 1, 6, 12 and 24Function and physical activity were assessed by assessed by WOMAC function sub-score in the signal knee. The criteria for assessment of the functional classification according to the American Rheumatism Association (ARA) were as follows (Hochberg et al 1992): I. Completely able to perform usual activities of daily living (self-care, vocational and avocational) II. Able to perform usual self-care and vocational activities, but limited in avocational activities. III. Able to perform usual self-care activities, but limited in vocational and avocational activities. IV. Limited ability to perform usual self-care activities, vocational and avocational activities. Self-care activities included dressing, feeding, bathing, grooming, and toileting. Avocational (recreational and/or leisure) and vocational (work, school, homemaking) activities were patient-desired and age- and sex-specific.
Questionnaire to Assess Stiffness in the Signal Knee.Baseline to month 24WOMAC's stiffness subscore was used to assess the stiffness in the signal knee. WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the degree of joint stiffness for when performing each daily function listed in the questionnaire. 0 is no stiffness (best), 100 is extreme stiffness (worst). The total function sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 200. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less stiffness). Patients were instructed not to take analgesics for 3 days prior to the WOMAC test.
Bone & Cartilage Metabolism Biochemical Marker Change (Percentage).From baseline to 24 monthsThe central laboratory analyzed serum CTX-I (S-Crosslaps, Elecsys) and osteocalcin as well as urine CTX I/creatinine and CTX-II/creatinine. These biomarkers were analysed in order to assess the cartilage and bone turonver ratio to baseline at month 24.
Questionnaire to Assess PainBaseline, month 1, month 6, month 12, month 24Pain was assessed by the WOMAC subscore in the signal knee by visit. Patients assessed their current pain level using a 100 mm visual analogue scales (VAS) by placing an X on the line that best describes his/her pain, where 0 equaled No Pain and 100 equaled Worst Pain Imaginable. Patients were instructed not to take analgesics for 3 days prior to the VAS.
Questionnaire to Assess Health-related Quality of LifeFrom baseline to month 24Health-related quality of life was assessed by the EQ-5D questionnaire, which is a patient questionnaire for measure of health, developed by the EuroQol Group.The EQ-5D questionnaire was administered to patients in order to measure change in health-related quality of life (HRQoL) over 2 years. The subjects marks on a VAS scale from 0 to 100 the number that best describes their health today (0 is worst imaginable health state and 100 is best imaginable health state). The change from baseline in the EQ-5D VAS was calculated.
Knee Disease Progression Assessed by MRIFrom baseline to month 12 and month 24Knee cartilage volume and thickness was assessed by MRI in patients from the sites in Ballerup, Denmark, the Czech Republic, and Romania using a quality controlled low-field 0.18T C-Span scanner from Esaote dedicated to the imaging of extremities. The same solenoid coil was used for all patients at a given site.

Countries

Belgium, Canada, Czechia, Denmark, Hong Kong, Poland, Romania, Spain, United Kingdom, United States

Participant flow

Recruitment details

Patients were enrolled at 18 centers in 10 countries: 6 centers in the US, 1 center in the UK, 1 center in Spain,1 center in the Czech Republic, 3 centers in Denmark, 1 center in Hong Kong, 2 centers in Poland, 1 center in Romania, 1 center in Belgium and 1 center in Canada. First patient randomized: 1 Aug 08 Last patient visit: 10 May 2011

Participants by arm

ArmCount
SMC021 Oral Calcitonin
0.8 mg SMC021 Oral Calcitonin twice daily
521
SMC021 Placebo
1 SMC021 Placebo tablet twice daily
509
Total1,030

Baseline characteristics

CharacteristicSMC021 Oral CalcitoninSMC021 PlaceboTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
229 Participants221 Participants450 Participants
Age, Categorical
Between 18 and 65 years
292 Participants288 Participants580 Participants
Age, Continuous64.4 years
STANDARD_DEVIATION 7
64.2 years
STANDARD_DEVIATION 6.8
64.3 years
STANDARD_DEVIATION 6.9
Region of Enrollment
Belgium
7 participants7 participants14 participants
Region of Enrollment
Canada
11 participants8 participants19 participants
Region of Enrollment
Czech Republic
36 participants35 participants71 participants
Region of Enrollment
Denmark
263 participants264 participants527 participants
Region of Enrollment
Hong Kong
72 participants72 participants144 participants
Region of Enrollment
Poland
67 participants66 participants133 participants
Region of Enrollment
Romania
9 participants9 participants18 participants
Region of Enrollment
Spain
4 participants2 participants6 participants
Region of Enrollment
United Kingdom
26 participants25 participants51 participants
Region of Enrollment
United States
26 participants21 participants47 participants
Sex: Female, Male
Female
321 Participants305 Participants626 Participants
Sex: Female, Male
Male
200 Participants204 Participants404 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
474 / 520459 / 508
serious
Total, serious adverse events
77 / 52080 / 508

Outcome results

Primary

Joint Space Width (JSW) in the Medial Tibia-femoral Knee Joint in the Signal Knee Measured by X-ray Change From Baseline Over 24 Months

The signal knee was chosen prior to randomization based on which knee met the inclusion and exclusion criteria. The JSW is the space measured in mm between the 2 bones in the knee joint and this is assessed by x-ray. The JSW decreases with disease progression. The lower limit for participation in the trial were 2 mm JSW. There were no upper limit as long as inclusion and exclusion criteria were met. The outcome was measured as a change in JSW from baseline to month 24.

Time frame: Change from baseline to 24 months

Population: The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication. There were 2 patients in the randomized population who did not receive any study drug and where therefore excluded from the ITT analysis.

ArmMeasureValue (MEAN)Dispersion
SMC021 Oral CalcitoninJoint Space Width (JSW) in the Medial Tibia-femoral Knee Joint in the Signal Knee Measured by X-ray Change From Baseline Over 24 Months-0.32 mmStandard Deviation 0.693
SMC021 PlaceboJoint Space Width (JSW) in the Medial Tibia-femoral Knee Joint in the Signal Knee Measured by X-ray Change From Baseline Over 24 Months-0.40 mmStandard Deviation 0.768
Primary

Pain Subscore Change From Baseline Over 24 Months as Assessed by Western Ontario and McMaster Universities Arthritis (WOMAC) Index

WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the pain associated with performing each daily activity listed in the questionnaire. 0 is no pain (best), 100 is extreme pain (Worst). The total pain sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 500. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less pain).

Time frame: Change from baseline to 24 months

Population: The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication. There were 2 patients in the randomized population who did not receive any study drug and where therefore excluded from the ITT analysis.

ArmMeasureValue (MEAN)Dispersion
SMC021 Oral CalcitoninPain Subscore Change From Baseline Over 24 Months as Assessed by Western Ontario and McMaster Universities Arthritis (WOMAC) Index-80.6 Units on a scaleStandard Deviation 112.22
SMC021 PlaceboPain Subscore Change From Baseline Over 24 Months as Assessed by Western Ontario and McMaster Universities Arthritis (WOMAC) Index-87.9 Units on a scaleStandard Deviation 116.25
Secondary

Bone & Cartilage Metabolism Biochemical Marker Change (Percentage).

The central laboratory analyzed serum CTX-I (S-Crosslaps, Elecsys) and osteocalcin as well as urine CTX I/creatinine and CTX-II/creatinine. These biomarkers were analysed in order to assess the cartilage and bone turonver ratio to baseline at month 24.

Time frame: From baseline to 24 months

Population: The number of participants analysed for these outcomes were a total of 150 subjects from the intent-to-treat (ITT) population evenly distributed across sites, all with completed baseline as well as all follow-up visits.

ArmMeasureGroupValue (MEAN)Dispersion
SMC021 Oral CalcitoninBone & Cartilage Metabolism Biochemical Marker Change (Percentage).Serum CTX-I (ng/mL)50.6 percentage of changeStandard Deviation 83.74
SMC021 Oral CalcitoninBone & Cartilage Metabolism Biochemical Marker Change (Percentage).Serum Osteocalcin (ng/mL)3.6 percentage of changeStandard Deviation 37.42
SMC021 Oral CalcitoninBone & Cartilage Metabolism Biochemical Marker Change (Percentage).24-h urine CTX-I/creatinine (µg/mmol)9.8 percentage of changeStandard Deviation 85.95
SMC021 Oral CalcitoninBone & Cartilage Metabolism Biochemical Marker Change (Percentage).24-h urine CTX-II/creatinine (ng/mmol)2.6 percentage of changeStandard Deviation 63.13
SMC021 PlaceboBone & Cartilage Metabolism Biochemical Marker Change (Percentage).24-h urine CTX-II/creatinine (ng/mmol)2.3 percentage of changeStandard Deviation 51.07
SMC021 PlaceboBone & Cartilage Metabolism Biochemical Marker Change (Percentage).Serum CTX-I (ng/mL)40.6 percentage of changeStandard Deviation 45.52
SMC021 PlaceboBone & Cartilage Metabolism Biochemical Marker Change (Percentage).24-h urine CTX-I/creatinine (µg/mmol)7.2 percentage of changeStandard Deviation 44.36
SMC021 PlaceboBone & Cartilage Metabolism Biochemical Marker Change (Percentage).Serum Osteocalcin (ng/mL)3.9 percentage of changeStandard Deviation 26.32
Secondary

Knee Disease Progression Assessed by MRI

Knee cartilage volume and thickness was assessed by MRI in patients from the sites in Ballerup, Denmark, the Czech Republic, and Romania using a quality controlled low-field 0.18T C-Span scanner from Esaote dedicated to the imaging of extremities. The same solenoid coil was used for all patients at a given site.

Time frame: From baseline to month 12 and month 24

Population: Subset of patients from the sites in Ballerup (Denmark), Czech Republic and Romania

ArmMeasureGroupValue (MEAN)Dispersion
SMC021 Oral CalcitoninKnee Disease Progression Assessed by MRICartilage Volume Month 123.4 percentage of changeStandard Deviation 9.11
SMC021 Oral CalcitoninKnee Disease Progression Assessed by MRICartilage Volume Month 242.6 percentage of changeStandard Deviation 10.18
SMC021 Oral CalcitoninKnee Disease Progression Assessed by MRICartilage Thickness Month 124.7 percentage of changeStandard Deviation 10.64
SMC021 Oral CalcitoninKnee Disease Progression Assessed by MRICartilage Thickness Month 244.5 percentage of changeStandard Deviation 10.78
SMC021 PlaceboKnee Disease Progression Assessed by MRICartilage Thickness Month 244.1 percentage of changeStandard Deviation 8.67
SMC021 PlaceboKnee Disease Progression Assessed by MRICartilage Volume Month 123.0 percentage of changeStandard Deviation 13.16
SMC021 PlaceboKnee Disease Progression Assessed by MRICartilage Thickness Month 124.7 percentage of changeStandard Deviation 8.24
SMC021 PlaceboKnee Disease Progression Assessed by MRICartilage Volume Month 243.5 percentage of changeStandard Deviation 12.73
Secondary

Questionnaire to Assess Function and Physical Activity

Function and physical activity were assessed by assessed by WOMAC function sub-score in the signal knee. The criteria for assessment of the functional classification according to the American Rheumatism Association (ARA) were as follows (Hochberg et al 1992): I. Completely able to perform usual activities of daily living (self-care, vocational and avocational) II. Able to perform usual self-care and vocational activities, but limited in avocational activities. III. Able to perform usual self-care activities, but limited in vocational and avocational activities. IV. Limited ability to perform usual self-care activities, vocational and avocational activities. Self-care activities included dressing, feeding, bathing, grooming, and toileting. Avocational (recreational and/or leisure) and vocational (work, school, homemaking) activities were patient-desired and age- and sex-specific.

Time frame: From baseline to months 1, 6, 12 and 24

Population: The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication.

ArmMeasureGroupValue (MEAN)Dispersion
SMC021 Oral CalcitoninQuestionnaire to Assess Function and Physical ActivityMonth 1-4.8 percentage of changeStandard Deviation 44.89
SMC021 Oral CalcitoninQuestionnaire to Assess Function and Physical ActivityMonth 6-22.6 percentage of changeStandard Deviation 49.03
SMC021 Oral CalcitoninQuestionnaire to Assess Function and Physical ActivityMonth 12-28.0 percentage of changeStandard Deviation 53.97
SMC021 Oral CalcitoninQuestionnaire to Assess Function and Physical ActivityMonth 24-30.3 percentage of changeStandard Deviation 77.51
SMC021 PlaceboQuestionnaire to Assess Function and Physical ActivityMonth 12-28.4 percentage of changeStandard Deviation 59.79
SMC021 PlaceboQuestionnaire to Assess Function and Physical ActivityMonth 1-1.9 percentage of changeStandard Deviation 131.2
SMC021 PlaceboQuestionnaire to Assess Function and Physical ActivityMonth 24-25.1 percentage of changeStandard Deviation 143.05
SMC021 PlaceboQuestionnaire to Assess Function and Physical ActivityMonth 6-17.9 percentage of changeStandard Deviation 64.15
Secondary

Questionnaire to Assess Health-related Quality of Life

Health-related quality of life was assessed by the EQ-5D questionnaire, which is a patient questionnaire for measure of health, developed by the EuroQol Group.The EQ-5D questionnaire was administered to patients in order to measure change in health-related quality of life (HRQoL) over 2 years. The subjects marks on a VAS scale from 0 to 100 the number that best describes their health today (0 is worst imaginable health state and 100 is best imaginable health state). The change from baseline in the EQ-5D VAS was calculated.

Time frame: From baseline to month 24

Population: The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication.

ArmMeasureValue (MEAN)Dispersion
SMC021 Oral CalcitoninQuestionnaire to Assess Health-related Quality of Life13.70 percentage of changeStandard Deviation 38.763
SMC021 PlaceboQuestionnaire to Assess Health-related Quality of Life11.82 percentage of changeStandard Deviation 40.645
Secondary

Questionnaire to Assess Pain

Pain was assessed by the WOMAC subscore in the signal knee by visit. Patients assessed their current pain level using a 100 mm visual analogue scales (VAS) by placing an X on the line that best describes his/her pain, where 0 equaled No Pain and 100 equaled Worst Pain Imaginable. Patients were instructed not to take analgesics for 3 days prior to the VAS.

Time frame: Baseline, month 1, month 6, month 12, month 24

Population: The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication.

ArmMeasureGroupValue (MEAN)Dispersion
SMC021 Oral CalcitoninQuestionnaire to Assess PainMonth 1-6.7 percentage of changeStandard Deviation 49.5
SMC021 Oral CalcitoninQuestionnaire to Assess PainMonth 6-26.9 percentage of changeStandard Deviation 51.73
SMC021 Oral CalcitoninQuestionnaire to Assess PainMonth 12-31.0 percentage of changeStandard Deviation 68.05
SMC021 Oral CalcitoninQuestionnaire to Assess PainMonth 24-35.1 percentage of changeStandard Deviation 91.63
SMC021 PlaceboQuestionnaire to Assess PainMonth 24-37.1 percentage of changeStandard Deviation 77.55
SMC021 PlaceboQuestionnaire to Assess PainMonth 1-9.1 percentage of changeStandard Deviation 45.26
SMC021 PlaceboQuestionnaire to Assess PainMonth 12-34.6 percentage of changeStandard Deviation 61.3
SMC021 PlaceboQuestionnaire to Assess PainMonth 6-26.9 percentage of changeStandard Deviation 50.43
Secondary

Questionnaire to Assess Stiffness in the Signal Knee.

WOMAC's stiffness subscore was used to assess the stiffness in the signal knee. WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the degree of joint stiffness for when performing each daily function listed in the questionnaire. 0 is no stiffness (best), 100 is extreme stiffness (worst). The total function sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 200. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less stiffness). Patients were instructed not to take analgesics for 3 days prior to the WOMAC test.

Time frame: Baseline to month 24

Population: The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication.

ArmMeasureValue (MEAN)Dispersion
SMC021 Oral CalcitoninQuestionnaire to Assess Stiffness in the Signal Knee.-26.1 percentage of changeStandard Deviation 90.88
SMC021 PlaceboQuestionnaire to Assess Stiffness in the Signal Knee.-20.3 percentage of changeStandard Deviation 179.22

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026